TY - JOUR T1 - Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients JF - In Vivo JO - In Vivo SP - 3631 LP - 3638 DO - 10.21873/invivo.12209 VL - 34 IS - 6 AU - JENNIFER MORITZ AU - THOMAS BAUERNHOFER AU - SEBASTIAN MANNWEILER AU - TANJA LANGSENLEHNER AU - KARL PUMMER AU - NADIA DANDACHI AU - MARTIN PICHLER Y1 - 2020/11/01 UR - http://iv.iiarjournals.org/content/34/6/3631.abstract N2 - Background/Aim: Carboplatin-containing treatment regimens demonstrate moderate efficacy in metastatic castration-resistant prostate cancer (mCRPC). In this study, we retrospectively analyzed the efficacy of carboplatin in relation to blood-based parameters. Patients and Methods: A retrospective chart review was performed for 20 patients with mCRPC who received carboplatin in a single center. Results: Median overall survival was 3.8 months (95%CI=1.5-7.1), median progression-free survival was 1.7 months. We observed two partial remissions (PR, 10%), four stable diseases (SD, 20%) and 14 disease progressions (PD, 70%), resulting in a clinical benefit rate of 30%. A doubling of NSE (neurone specific enolase) values was associated with a 19% absolute higher response rate (95%CI=14-23, p=0.027). All other laboratory parameters failed as predictive markers of response to carboplatin. In univariate Cox regression analysis, only NSE was significantly associated with impaired PFS (HR=0.7, 95%CI=0.56-0.96, p=0.030). Conclusion: Carboplatin showed moderate efficacy against mCRPC in this unselected population of patients and NSE levels may help to predict the success of this treatment. ER -